PMID- 28866819
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20240326
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Print)
IS  - 1357-0560 (Linking)
VI  - 34
IP  - 10
DP  - 2017 Sep 2
TI  - Fluorescence in situ hybridization as prognostic predictor of tumor recurrence 
      during treatment with Bacillus Calmette-Guerin therapy for intermediate- and 
      high-risk non-muscle-invasive bladder cancer.
PG  - 172
LID - 10.1007/s12032-017-1033-z [doi]
LID - 172
AB  - A significant number of patients with intermediate- or high-risk bladder cancer 
      treated with intravesical Bacillus Calmette-Guerin (BCG) immunotherapy are 
      non-responders to this treatment. Since we cannot predict in which patients BCG 
      therapy will fail, markers for responders are needed. UroVysion((R)) is a 
      multitarget fluorescence in situ hybridization (FISH) test for bladder cancer 
      detection. The aim of this study was to evaluate whether FISH can be used to 
      early identify recurrence during treatment with BCG. In a multicenter, 
      prospective study, three bladder washouts at different time points during 
      treatment (t (0) = week 0, pre-BCG, t (1) = 6 weeks following TURB, t 
      (2) = 3 months following TURB) were collected for FISH from patients with bladder 
      cancer treated with BCG between 2008 and 2013. Data on bladder cancer recurrence 
      and duration of BCG maintenance therapy were recorded. Thirty-six (31.6%) out of 
      114 patients developed a recurrence after a median of 6 months (range 2-32). No 
      significant association was found between a positive FISH test at t (0) or t (1) 
      and risk of recurrence (p = 0.79 and p = 0.29). A positive t (2) FISH test was 
      associated with a higher risk of recurrence (p = 0.001). Patients with a positive 
      FISH test 3 months following TURB had a 4.0-4.6 times greater risk of developing 
      a recurrence compared to patients with a negative FISH. Patients with a positive 
      FISH test 3 months following TURB and induction BCG therapy have a higher risk of 
      developing tumor recurrence. FISH can therefore be a useful additional tool for 
      physicians when determining a treatment strategy.
FAU - Liem, Esmee I M L
AU  - Liem EIML
AD  - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
      Amsterdam, The Netherlands. e.i.liem@amc.uva.nl.
FAU - Baard, Joyce
AU  - Baard J
AD  - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
      Amsterdam, The Netherlands.
FAU - Cauberg, Evelyne C C
AU  - Cauberg ECC
AD  - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
      Amsterdam, The Netherlands.
FAU - Bus, Mieke T J
AU  - Bus MTJ
AD  - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
      Amsterdam, The Netherlands.
FAU - de Bruin, D Martijn
AU  - de Bruin DM
AD  - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
      Amsterdam, The Netherlands.
AD  - Department of Biomedical Engineering and Physics, Academic Medical Center, 
      Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
FAU - Laguna Pes, M Pilar
AU  - Laguna Pes MP
AD  - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
      Amsterdam, The Netherlands.
FAU - de la Rosette, Jean J M C H
AU  - de la Rosette JJMCH
AD  - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
      Amsterdam, The Netherlands.
FAU - de Reijke, Theo M
AU  - de Reijke TM
AD  - Department of Urology, Academic Medical Center, Meibergdreef 9, 1105 AZ, 
      Amsterdam, The Netherlands.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170902
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (BCG Vaccine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - BCG Vaccine/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunotherapy/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/genetics
MH  - Prospective Studies
MH  - Survival Analysis
MH  - Urinary Bladder Neoplasms/*genetics/mortality/pathology/*therapy
PMC - PMC5581817
OTO - NOTNLM
OT  - Bacillus Calmette-Guerin (BCG)
OT  - Biomarker
OT  - Bladder cancer
OT  - Fluorescence in situ hybridization (FISH)
OT  - Non-muscle-invasive bladder carcinoma (NMIBC)
OT  - Recurrence
COIS- CONFLICT OF INTEREST: The authors declare no conflicts of interest. HUMAN AND 
      ANIMAL RIGHTS: The medical ethical committee of the Academic Medical Center 
      reviewed the study protocol and concluded that the study did not imply that 
      participants of the study were subjected to procedures or were required to follow 
      rules of behavior according the 'Wet Medisch-wetenschappelijk onderzoek met 
      mensen' (WMO). The WMO is the Medical Research involving Human Beings Act. When 
      the research does not fall under the scope of the WMO, then the protocol does not 
      have to be reviewed by an accredited medical research ethical committee. 
      Therefore, approval of the medical ethical committee was not required. A copy of 
      this decision is available. INFORMED CONSENT: Informed consent was verbally 
      obtained from all participants prior to inclusion.
EDAT- 2017/09/04 06:00
MHDA- 2018/06/19 06:00
PMCR- 2017/09/02
CRDT- 2017/09/04 06:00
PHST- 2017/08/04 00:00 [received]
PHST- 2017/08/29 00:00 [accepted]
PHST- 2017/09/04 06:00 [entrez]
PHST- 2017/09/04 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
PHST- 2017/09/02 00:00 [pmc-release]
AID - 10.1007/s12032-017-1033-z [pii]
AID - 1033 [pii]
AID - 10.1007/s12032-017-1033-z [doi]
PST - epublish
SO  - Med Oncol. 2017 Sep 2;34(10):172. doi: 10.1007/s12032-017-1033-z.